DEPEND stands for Dosage and Efficacy of Probucol-induced apoE to Negate cognitive Deterioration.

This proof-of-concept program, in two phases, was intended to study the effect of probucol, an old cholesterol-lowering drug on apoE protein levels in cerebrospinal fluid and on other vascular biomarkers in blood and CSF.

Recruitment

Phase A – 23 participants – COMPLETED

Phase B –  not started

Clinical trial.gov NCT02707458